Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 9/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010728 | 0.90 | CFD (0.52) | TBXAS1CFDPRMT5PKM | |
| SCHEMBL21438395 | 0.90 | CFD (0.52) | TBXAS1CFDPRMT5PKM | |
| SCHEMBL23217590 | 0.87 | CFD (0.54) | CFDTHRATHRBPPARGPPARD | |
| SCHEMBL23217703 | 0.84 | CFD (0.57) | TBXAS1CFDDHFR | |
| SCHEMBL21455780 | 0.81 | CFD (0.49) | CFDPRMT5 | |
| SCHEMBL23218765 | 0.81 | TBXAS1 (0.43) | TBXAS1CFDTHRATHRBPRMT5 | |
| SCHEMBL29853099 | 0.81 | TBXAS1 (0.43) | TBXAS1CFDTHRATHRBPRMT5 | |
| SCHEMBL23217674 | 0.81 | SMN1; SMN2 (0.39) | THRBPKM | |
| SCHEMBL21438939 | 0.80 | CFD (0.42) | CFDPRMT5 | |
| SCHEMBL21438235 | 0.80 | CFD (0.42) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |